Rett Syndrome Bulgaria

Rett Syndrome Bulgaria Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Rett Syndrome Bulgaria, Medical and health, Sofia.

https://www.facebook.com/share/p/1B5ZtdYd2o/
10/02/2026

https://www.facebook.com/share/p/1B5ZtdYd2o/

Today Neurogene shared a summary of previously shared interim data (Nov 25) from its Phase 1/2 NGN-401 gene therapy trial for Rett syndrome.

At the low (1E15 vg dose), NGN-401 has been generally well tolerated, with treatment-related side effects reported as mild to moderate. Importantly, no extreme immune responses have been observed.

In addition, participating children (ages 4–10) have continued to gain new skills across multiple area, such as hand use, movement, communication, and autonomic function, with no loss of previously gained skills reported to date.

NGN-401 is not approved outside of clinical trials.

Neurogene has now begun enrollment for its Phase 3 Embolden™ trial now as well as continuing to monitor the participants from the Phase 1/2 trial.

We are encouraged by continued progress and grateful to all the families and participants whose courage is moving Rett research forward. 💜

You can read more at the link below 🙏

https://www.neurogene.com/wp-content/uploads/2026/02/Neurogene-Phase-1-2-Interim-Data-Summary-Jan2026.pdf

09/01/2026

Taysha Clinical Trial Update for the Rett Community

Taysha Gene Therapies has shared an update on its clinical trials for TSHA-102, an investigational gene therapy for Rett syndrome.

The first participant has received the TSHA-102 treatment in the REVEAL Pivotal Study, and more children and young adults are joining at different sites. The FDA has also approved a new study called ASPIRE for younger girls. Everyone in both studies is expected to get the treatment by the middle of 2026, and results from earlier REVEAL participants will be shared in early 2026. REVEAL is studying how safe and effective the therapy is for girls and young women ages 6–21, looking at improvements in skills like using their hands, moving around, and communicating. ASPIRE is testing safety and early effects in girls ages 2–3 to help see if the treatment could be approved for younger children too.

We’re encouraged by continued progress and remain hopeful for the Rett community 💜

Learn More:
Full press release here - https://ir.tayshagtx.com/node/10036/pdf
REVEAL study sites and contact info are available on ClinicalTrials.gov (NCT05606614).

09/01/2026
05/01/2026

🧠 Mini-Post 3: The Neurons Are There — They’re Just Less Mature
A dad’s version — simple, honest, research-accurate.

In the last post, we talked about how the Rett brain is smaller — but not shrinking.
Now we go one layer deeper into the question every parent eventually asks:

“If the brain isn’t degenerating, then what’s actually happening inside?”

Here’s the part that changed everything for me:

The neurons are there.
They didn’t die.
They didn’t disappear.
They just didn’t fully mature.

And that single truth explains so much — not just about Rett syndrome, but about MECP2-related disorders as a whole.

🟣 What “immature neurons” actually means (Dad Translation)

In a typical brain, neurons grow up the way kids do:

• they get bigger
• they grow complex branches (called dendrites)
• they form stable connections
• they learn to fire in rhythm
• they join networks that work together

In Rett and other MECP2 disorders, the neurons start this process…
but they don’t finish it.

This isn’t about behavior.
This is about physical structure.

If you look at a diagram comparing neurons, you’ll see it clearly:
the MECP2-affected neuron still has branches — they’re just shorter and fewer.

And notice what isn’t happening:

• it isn’t dead
• it isn’t damaged
• it isn’t missing

It’s alive.
It’s present.
It’s trying.

It’s just younger than it should be for the job it’s being asked to do.

It’s like asking a middle-school orchestra to play a professional symphony.
The instruments are there.
The players are there.
But the timing, coordination, and experience aren’t fully developed yet.

🟣 Why this happens (The Conductor)

This goes back to MECP2 — the “conductor” gene.

MECP2 doesn’t tell neurons what to be.
It tells them when to grow up.

When MECP2 isn’t working properly — whether in classic Rett, atypical Rett, or other MECP2-related disorders:

• neurons stay smaller
• dendrites stay shorter
• synapses stay unstable
• networks stay uncoordinated

Not broken.
Not dying.
Just stuck in an earlier developmental stage.

🟣 Why this explains “regression”

Parents often describe regression like this:

“She had the skill… and then it slipped away.”

But here’s what the research actually shows:

The skill wasn’t erased.
The system supporting it became unstable.

An immature neuron can fire one day and misfire the next.
A network that isn’t fully synchronized can’t hold a skill under stress.
A circuit that’s under-connected can’t maintain consistency.

This is why our kids have:

• good days and hard days
• bursts of ability followed by silence
• moments of clarity followed by storms

It’s not loss.
It’s instability.

And instability can be supported.

🟣 Why this matters for parents

Because once you understand that the neurons are still there, everything changes:

• your child’s mind is not disappearing
• their intelligence is not fading
• their awareness is not slipping away

They are present.
They are processing.
They are trying — harder than most people will ever understand.

The challenge is expression, not existence.

🟣 Why this gives me hope

If neurons were dying, we’d be fighting a losing battle.

But because they’re still there — just less mature — it means:

• they can still grow
• they can still strengthen
• they can still connect
• they can still respond to treatment
• they can still benefit from MECP2-targeted therapies

And this is why the 2007 Adrian Bird Lab study was such a breakthrough — especially for families with older kids.

When MECP2 was restored in adult mice — not developing pups — the neurons didn’t just survive.

They woke up.

They matured.
They reconnected.
They regained function.

Not perfectly.
Not instantly.
But undeniably.

That matters — because it means this isn’t just about early childhood windows.
It means the brain retains capacity, even later in life.

That’s the reversibility principle —
and it starts right here, with immature neurons waiting for better instructions.

Next up:
🧠 Mini-Post 4 — “Dendrites: The Wiring That Didn’t Fully Branch.”


12/11/2025

Neurogene is focused on developing life-changing genetic medicines for patients & families affected by rare, devastating neurological diseases.

https://www.facebook.com/share/p/1EgB7QUX1e/
07/11/2025

https://www.facebook.com/share/p/1EgB7QUX1e/

💜 Rett Syndrome & MECP2 Duplication — Two Sides of the Same Gene 💜

Even though it’s not Rett Syndrome Awareness Month, every month is awareness month when you live it.
So let’s talk about something that often confuses people — how Rett Syndrome and MECP2 Duplication Syndrome are connected, yet completely different.

Both disorders come from the same gene — MECP2, found on the X chromosome — but what happens inside that gene determines the path each family walks.

🧬 The Rett Syndrome Side — When MECP2 Is Missing or Misfiring

In Rett Syndrome, a loss-of-function mutation in the MECP2 gene means the protein either doesn’t work as it should, or it’s missing altogether.
Without this protein doing its job, the brain struggles to regulate the many genes that rely on it for timing, communication, and balance.

That’s why Rett can affect almost every system of the body — breathing, movement, digestion, sleep, and communication.

💜 It’s seen mostly in girls, because boys with the same mutation often don’t survive infancy unless mosaic or Klinefelter (XXY).

It’s not a degenerative disease — the brain doesn’t die off — it’s a disorder of arrested development. The wiring is there, but the signal can’t always get through.

🔁 The Duplication Side — When MECP2 Is Too Active

Now imagine the opposite problem: too much MECP2.
That’s MECP2 Duplication Syndrome, where extra copies of the gene create too much of the protein.
Instead of underactivation, the system becomes overloaded.

This condition appears most often in boys and can cause:

Low muscle tone and developmental delay

Seizures and frequent infections

Motor and cognitive challenges

Speech and communication difficulties

Some girls can be affected too, depending on how their X chromosomes activate or silence.

⚖️ Two Different Paths — One Common Thread

What’s fascinating is how these two disorders mirror each other — one from too little MECP2, one from too much.
Both affect how the brain develops, communicates, and maintains balance.
Both lead to complex medical and neurological challenges — and both are teaching the scientific community how vital MECP2 is to human life.

When researchers study one, they learn about the other.
They’re discovering that the key to treating either isn’t just adding or taking away — it’s balance.
Restoring MECP2 function to that delicate, God-designed level where the brain can find peace again.

🔬 Why It Matters — Hope in the Details

Every discovery about MECP2 — whether it comes from Rett Syndrome or MECP2 Duplication research — moves us all forward.
Because the more we understand how this one gene works, the closer we get to therapies that bring real, lasting change.

And that’s why awareness matters every day.
Because our daughters and sons living with these rare conditions deserve a world that sees them not as broken — but as the reason we fight for better science, better care, and better hope.

💜 The same gene that caused their struggle might one day hold the key to their healing. 💜

❤️🤹‍♀️

06/11/2025

Every voice deserves to be heard. 💜

Five years after its release, the Rett Syndrome Communication Guidelines remain a cornerstone of best practice in how we support communication in individuals with Rett syndrome.

From inspiring The Hive - a thriving professional network - to being woven into graduate programs across the U.S., its influence continues to expand.

Explore how collaboration, education, and compassion are driving better care: https://www.rettsyndrome.org/commsguide5/

06/11/2025

Today, Neurogene Inc. announced the dosing of the first participant in the Embolden™ registrational trial of NGN-401 gene therapy for Rett syndrome. The company shared that it expects to complete enrollment in this part of the trial within 3-6 months and that rapid trial ex*****on is underway with 12/13 clinical sites in the U.S. initiated.

For more information, read the full press release: https://ir.neurogene.com/news-releases/news-release-details/neurogene-announces-first-participant-dosed-emboldentm

Address

Sofia

Alerts

Be the first to know and let us send you an email when Rett Syndrome Bulgaria posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram